, indicates that mouse models of human cancer can serve as biologically relevant filters for complex human oncogenomes. More recent high-resolution genomics-based studies have proven that such cross-species comparisons enable the efficient identification of new oncogenes in human cancers 10, 11 , and re-sequencing of key genes in murine cancer models reveals conservation of somatic signature mutational events 12 . However, a limitation of mouse cancer models for comparative oncogenomics is the relatively benign cytogenetic profiles of most genetically engineered murine cancers 8, 10, 11, 13 . On the other hand, murine cancer genomes can be destabilized experimentally, to simulate the rampant chromosomal instability of human cancers, including those with telomere dysfunction, impaired DNA damage checkpoints such as Atm, dominant Trp53 mutant alleles, and defective DNA repair [14] [15] [16] [17] [18] [19] [20] [21] . These 'instability models' of cancer, coupled with high-resolution genomic technologies, hold the potential to provide highly informative systems for comparative oncogenomics.
In this study, we generated a murine lymphoma model that combines the genome-destabilizing impact of Atm deficiency and telomere dysfunction to effect T lymphomagenesis in a Trp53-dependent manner. We applied multiple genome analysis technologies to identify cancer-associated alterations shared between our mouse model and human cancers. These systematic cross-species comparisons uncovered many syntenic CNAs, not only in lymphomas of the T-cell lineage, but also in other human tumour types, emphasizing the common genetic and biological events in mouse models of cancer. Re-sequencing of candidate genes in syntenic CNAs readily identified FBXW7 and PTEN as commonly mutated genes in human T-ALL.
Results

Generation of murine T-cell lymphomas with highly complex genomes.
Nearly all Atm 2/2 mice develop thymic lymphomas 22 with moderate levels of aneuploidy and recurrent chromosomal rearrangements 23 . In Terc 2/2 Atm 2/2 mice, telomere dysfunction suppresses lymphoma development, which may relate in part to Trp53 activation 20, 21 and/ or altered chromosomal dynamics 24 . To address this directly, we intercrossed Terc, Atm and Trp53 mutant mice to generate various genotypic combinations from this 'triple'-mutant colony (hereafter designated as 'TKO' for all genotypes) and found that telomere dysfunctional (that is, third (G 3 ) and fourth (G 4 (Fig. 1a) . Moreover, lymphomas from Trp53 1/2 TKO mice showed reduction to homozygosity in 14/15 specimens examined (Fig. 1b) , indicating strong genetic pressure to inactivate Trp53 during lymphomagenesis. These TKO tumours resembled those from conventional Atm 2/2 mice with effacement of thymic architecture by CD4 
/CD8
1 (less commonly CD4 2 /CD8 2 or mixed single/double positive) lymphoma cells (Fig. 1c, data not shown) . Together, these observations strongly suggest that an Atm-independent Trp53-dependent telomere checkpoint constrains lymphoma development.
We undertook spectral karyotype (SKY) analyses to quantify chromosomal rearrangements in nine telomere-deficient (G1-G4 Terc 2/2 ) and 9 telomere-intact (G0 ) TKO lymphomas ( Fig. 1d; Supplementary Fig. 1 ; Supplementary Table 1) . Relative to G0 tumours, G1-G4 TKO lymphomas showed a greater frequency of chromosome structural aberrations (0.34 versus 0.09 per chromosome, respectively, P , 0.0001, t-test), including multicentric chromosomes, non-reciprocal translocations, and p-p, p-q and q-q chromosome arm fusions involving homologous and/or non-homologous chromosomes. Several chromosomes (specifically, 2, 6, 8, 14, 15, 16, 17 and 19) were involved in significantly more dicentric and robertsonian-like rearrangements in G1-G4 relative to G0 TKO tumours (P , 0.05; t-test; Fig. 1e ), suggesting that these events provide adaptive mechanisms to tolerate telomere dysfunction and/or have causal roles in lymphoma development. TKO tumours acquire genomic lesions syntenic to those in human T-ALL. In the mouse, cancer-associated chromosomal rearrangements of the types described above are by-products of breakage-fusionbridge cycles associated with telomere dysfunction and defective Trp53 function 14 , and similar events can generate amplifications or deletions at the translocation site in human cells 25 . These processes, together with biological selection, drive emergence of clonal CNAs targeting cancer-relevant genes in the mouse 6, 15 . We therefore compiled high-resolution genome-wide array-CGH profiles of 35 TKO tumours (Supplementary Table 1 ) and 26 human T-ALL cell lines and tumours (Supplementary Table 2 ) for comparison. TKO profiles revealed marked genome complexity with all chromosomes exhibiting regional and focal recurrent CNAs (Fig. 1f) , some of which were observed in .40% of samples (for example, amplicons targeting distinct regions on mouse chromosomes 1, 2, 3, 4, 5, 9, 10, 12, 14, 15, 16, and 17; and deletions on 6, 11, 12, 13, 14, 16 and 19) , corresponding well with rearrangements detected by SKY.
In addition to recurrent physiological deletions of T-cell receptor (Tcr) loci ( Fig. 1f, arrows; Supplementary Fig. 2 ) as expected for T-cell derived tumours, we observed pathogenetically relevant recurrent genomic events in this instability model, such as a high-amplitude genomic event on chromosome 2. By SKY, this is a recurrent nonreciprocal translocation involving chromosome 2 (band A3) with different partner chromosomes ( Supplementary Fig. 3 ). By array-CGH, the CNAs in 4 independent TKO tumours shared a common boundary close to the 39 region of the Notch1 gene, with 2 additional tumours harbouring Notch1 focal amplifications (Supplementary Fig. 3 ; data not shown). NOTCH1 activation by carboxy-terminal structure alteration and point mutations is a signature event of human T-ALL 3, 26, 27 . Although the murine genomic rearrangements differ from NOTCH1 translocations in human T-ALL 27 , their common shared boundary involving Notch1 suggested potential relevance to the TKO tumours. Thus, we performed Notch1 re-sequencing in several TKO lymphomas lacking Notch1 genomic rearrangement and uncovered truncating insertion/deletion mutations and non-conservative amino acid substitutions in the Notch1 PEST and heterodimerization domains, as well as broader deletions within exon 34 encoding the PEST domain (Supplementary Fig. 4a ; Supplementary Table 1 ). This mutation spectrum is analogous to that observed in human T-ALL, because the PEST and heterodimerization domains are two hot spots of NOTCH1 mutation ( Supplementary Fig. 4a , see below) 3 . Biochemically, these mutations promote activation of mouse Notch1 as shown by higher levels of both full-length and the active cleaved form (V1744) 28 of Notch1 proteins ( Supplementary Fig. 4b ). Transcriptome profiling further showed upregulation of several Notch1 transcriptional targets including Ptcra, Hes1, Dtx1 and Cd3e, which correlated well with messenger RNA levels of Notch1 26 ( Supplementary Fig. 4c ). The observation of physiological deletion of Tcr loci and a humanlike pattern of Notch1 genomic and mutational events in TKO tumours prompted the assessment of the extent to which other CNAs emerging in TKO lymphomas mirrored those seen in human T-ALL. To this end, we first defined the minimal common regions 
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(MCRs, regions overlapping in more than one tumour as defined in Methods) in the TKO genome using an established algorithm with criteria of CNA width #10 Mb (megabases) and amplitude .0.75 (log 2 scale), yielding 160 MCRs with average sizes of 2.12 Mb (0.15-9.82 Mb) and 2.33 Mb (0.77-9.6 Mb) for amplifications and deletions, respectively (Supplementary Table 3 ). This frequency of genomic alterations is comparable to most human cancer genomes (for example, see below) and significantly above the typical 20 to 40 events detected in most genetically engineered 'genome-stable' murine tumour models 8, 10, 11, 29 . Next, by orthologue mapping of genes resident within the MCRs of CNAs, we compared the TKO MCRs with similarly defined MCRs in human T-ALL to identify syntenic overlap. Here, 18 of the 160 MCRs (11%) were found to overlap across species (Table 1) ; the extent to which overlap occurred was significantly greater than that expected by chance alone (P 5 0.001 and 0.004 for deletions and amplifications, respectively). Moreover, these syntenic MCRs included several genes already implicated in T-ALL biology, such as Crebbp, Ikaros (also known as Ikzf1) and Abl1 (refs [30] [31] [32] . These data support the relevance of murine models to human cancer biology and their potential use for human cancer gene discovery through comparative oncogenomics. Frequent Fbxw7 inactivation in T-ALL. A few TKO tumours with minimal Notch1 expression exhibited elevated Notch4 or Jagged1 (Notch ligand) mRNA levels (data not shown), prompting a detailed examination of the genomic and expression status of components in the Notch pathway. Indeed, a syntenic MCR encompassing the Fbxw7 gene (MCR no. 18, Table 1 ; Fig. 2a ) was observed across species. Although extremely focal in humans (Fig. 2a) , the syntenic overlap made it unlikely that such deletion events represented copy number polymorphisms. (Fig. 2b) , these FBXW7 mutations in human T-ALL were predominantly mis-sense mutations, and particularly clustered in evolutionarily conserved arginine residues of the third and fourth WD40 domains involved in target binding 33 ( Fig. 2c) .
Moreover, re-sequencing of FBXW7 in matched normal bone marrows from several patients in complete remission showed that the two most common mutations observed (R465, R479) were acquired somatically (data not shown 35 . PEST domain mutations in human T-ALL prolong the half-life of intracellular NOTCH1, indicating that FBXW7 loss may cause similar phenotypic effects. To address this, we characterized the cell lines and clinical samples for NOTCH1 mutations (Supplementary Tables 2a, 2c, 4 and 5) . Interestingly, there was no association between known functional mutations of NOTCH1 (N-terminal (HD-N) and C-terminal (HD-C) heterodimerization domains and PEST domains) and FBXW7 mutations (P 5 0.16). However, among samples with NOTCH1 mutations, FBXW7 mutations were found less frequently in samples with a mutated PEST domain (4/19; 21%) than samples with mutations of only the HD-N or HD-C domain (13/20; 65%; P 5 0.009). This is consistent with the hypothesis that mutations of FBXW7 and the PEST domain of NOTCH1 target the same degradation pathway, and little selective advantage accrues to the majority of tumours from mutating both components. On the other hand, the lack of NOTCH1 and FBXW7 mutation mutual exclusivity suggests that FBXW7 affects other pathways in addition to NOTCH (see discussion). Frequent Pten inactivation in mouse and human T-cell malignancy. Focal deletion on chromosome 19, centring on Pten, was among the most common genomic events in TKO lymphomas (Table 1 ; Fig. 1f) . Array-CGH, coupled with real-time genomic PCR, documented homozygous deletions of Pten in 15/35 (43%) TKO lymphomas ( Fig. 3; Supplementary Fig. 5 ). PTEN is a well-known tumour suppressor 36 and the inactivation of the homologue in the murine thymus is known to generate T-cell tumours 37 . Correspondingly, array-CGH confirmed that 4 out of 26 human T-ALL samples had PTEN locus rearrangements. Additionally, re-sequencing of the 61 T-ALL cell lines and clinical specimens (Supplementary Table 2 ) Each murine TKO MCR with syntenic overlap with an MCR in the human T-ALL data set is listed-separated by amplification and deletion-along with its chromosomal location (Cytoband/Chr) and base number (Start and End, in base pairs). The minimal size of each MCR is indicated in base pairs (bp). Peak ratio refers to the maximal log 2 array-CGH ratio for each MCR. Rec refers to the number of tumours in which the MCR was defined.
uncovered inactivating PTEN mutations in 9 cases, none of which was found in public SNP databases. Each is predicted to cause protein truncation and is observed in other cancers 36 but shows no clear correlation with NOTCH1 mutations (Supplementary Tables 4 and  5 ). PTEN mutations were more frequent in cell lines (7/23; 30.4%) than in clinical specimens (2/38; 5.2%) (Supplementary Table 4) . Because these clinical specimens were newly diagnosed cases, whereas the cell lines were mostly established from relapses, this difference in mutation frequency may suggest that PTEN inactivation is a later event associated with progression, among other possibilities.
Northern and western blot analyses and transcriptome profiling of the TKO and human T-ALL samples revealed a broader collection of tumours with low to undetectable PTEN expression (Fig. 3b , data not shown) with elevated phospho-AKT. Moreover, AKT activation may have been driven by focal Akt1 amplification and Tsc1 loss in two TKO samples ( Fig. 3c; data not shown) . Lastly, the biological significance of Pten status in TKO lymphoma is supported by their sensitivity to Akt inhibition in a Pten-dependent manner ( Supplementary Fig. 6 ) in response to triciribine, a drug known to block Akt phosphorylation and inhibit cells dependent on the Akt pathway 38 .
Broad comparison of the TKO genome with diverse human cancers. Although cross-species comparison showed numerous concordant lesions in cancers of T-cell origin, the fact that this instability model is driven by mechanisms of fundamental relevance (telomere dysfunction and Trp53 mutation) to many cancer types suggested potentially broader relevance to other human cancers. A case in point is the PTEN example above; PTEN is a tumour suppressor for multiple cancers 36 . We therefore extended the cross-species comparative genomic analyses to 6 other human cancer types (n 5 421) of haematopoietic, mesenchymal and epithelial origins, including multiple myeloma (n 5 67) 39 , glioblastoma (n 5 38) (unpublished) and melanoma (n 5 123) (unpublished), as well as pancreatic (n 5 30) (unpublished), lung (n 5 63) 40 and colon adenocarcinomas (n 5 74) (unpublished). Compared to similarly defined MCR lists (that is, MCR width #10 Mb; Fig. 4a ) of each of these cancer types, we found that 102 (61 amplifications, 41 deletions) of 160 MCRs (64%) in the TKO genomes matched with at least 1 MCR in 1 human array-CGH data set, with strong statistical significance attesting to non-randomness of the overlap (Fig. 4a) . Confidence in the relevance of these syntenic events was bolstered by the observation that more than half of these syntenic MCRs (38 of 61 amplifications or 62%; 22 of 41 deletions or Thymus B  CA456  CA427  KM343  A791  A1005  A1252  A1040  A1240  A1052  A1060  A933  A934  A725  A785  A1118 TKO Lymphomas ARTICLES 53%) overlapped with MCRs recurrent in two or more human tumour types (Fig. 4b) . Moreover, a significant proportion of the TKO MCRs were evolutionarily conserved in human tumours of non-haematopoietic origin (Fig. 4c) . Among the 61 amplifications with syntenic hits, 58 of them (95%) were observed in solid tumours, whereas the remaining 3 were uniquely found in myeloma (Fig. 4c) . Similarly, 33 of 41 (80%) syntenic deletions were present in solid tumours (Fig. 4c ). Among these are Trp53, deleted in 5 of 7 human cancer types, and Myc amplifications in 6 human cancers. This substantial overlap with diverse human cancers was unexpected. Next, to provide an additional level of validation for these TKO genomic events, we determined whether these syntenic MCRs targeted known cancer genes. Mouse homologues were found for 237 of 363 genes listed on the Cancer Gene Census 41 , and of these, 24 were found within the 104 syntenic MCRs (Supplementary Table 6 ). These included 17 oncogenes in amplifications and 7 tumour suppressor genes in deletions. However, the majority of these syntenic MCRs do not contain known cancer genes, raising the strong possibility that resequencing that is focused on resident genes of syntenic MCRs may provide a high-yield strategy to identify somatic mutations in human cancers, a thesis supported by the FBXW7 and PTEN examples.
Discussion
We describe here the characterization of a mouse model of T-cell lymphoma engineered with telomere and checkpoint defects. In these unstable murine tumours, cytogenetic and copy number analyses reveal a level of genome complexity comparable to that of human solid tumours. The presence of rampant genome instability, and absence of an engineered dominantly acting oncogene, created a model system in which biological selection pressures drive acquired genomic events with potential relevance to human T-cell malignancy and/or cancer in general. In this model, murine cancers acquire widespread recurrent clonal CNAs targeting loci syntenic to alterations present in a human T-ALL as well as a large collection of diverse haematopoietic, mesenchymal and epithelial cancers. The relevance of these non-random syntenic events is supported on several levels, including the presence of syntenic MCRs in more than one human cancer type; the identification of MCRs harbouring known cancer genes; and the identification of somatic mutations in genes within conserved MCRs (FBXW7 and PTEN) .
Evolutionarily conserved genomic deletions targeting the FBXW7 and PTEN loci motivated re-sequencing of them in human and murine T-ALL samples, revealing frequent mutations. FBXW7 mutation has been described in about 5% of colorectal and ovarian cancers [42] [43] [44] , although its involvement in T-ALL has not been reported previously. As a key component of the E3 ubiquitin ligase that ubiquitinates NOTCH1, loss or mutation of FBXW7 is expected to be functionally equivalent to PEST domain mutation of NOTCH1, prolonging NOTCH1 half-life 35 . Indeed, a statistically significant anti-correlation is observed between presence of PEST domain mutations in NOTCH1 and presence of FBXW7 mutation in human T-ALL samples. However, the fact that several samples with FBXW7 mutations have wild-type NOTCH1 (5/22) strongly implies that other pathways may be affected by FBXW7 mutations in some cancers. Indeed, FBXW7 is known to promote degradation of other proteins implicated in lymphoma biology such as Aurora A (also known as AURKA), c-Jun (JUN), Cyclin E (CCNE1) and C-myc (MYC) 34, 35 , the latter of which is also a transcriptional target of NOTCH signalling 45 . In summary, the compelling synteny between TKO tumours and several human cancers of diverse origins demonstrates that engineered chromosomal instability in the mouse can engender genomic alterations similar to those observed in complex human oncogenomes, providing evidence that murine and human tumours experience common biological processes driven by the orthologous genetic events. These results provide support for the use of such murine models as a guidepost to focus and prioritize re-sequencing efforts in human cancer because cross-species synteny serves as a measure of validation by virtue of the evolutionary conservation and use of different genetic mechanisms (that is, mutation and copy number) involved. Furthermore, the mouse can facilitate the differentiation between somatic CNAs and copy number polymorphisms owing to the fragmentation of syntenic regions in the mouse and human genomes. We conclude that genomically unstable mouse cancer models represent a valuable resource for mining complex human cancer genomes.
METHODS SUMMARY
Terc Atm-and Terc Trp53-deficient mice described previously 21, 46 were interbred, maintained in pathogen-free facilities and followed for lymphoma development. Resultant TKO lymphomas were harvested from moribund animals and metaphase preparations of primary cultures were used for SKY profiling. DNA and RNA were extracted from the murine TKO tumours as well as from human cancer cell lines and tumours for performing array-CGH and transcriptome profiling, respectively. MCRs of 10 Mb or smaller were defined by described algorithms 39, 47 for murine lymphomas and each of the 6 different human cancer types. Syntenic overlap was determined based on orthologue mapping of MCR resident genes and statistic significance of the overlap calculated by permutation. Known cancer genes were as defined by the Cancer Gene Census 41 
